IPS Therapeutique (IPST) is a Contract Research Organization dedicated to the preclinical evaluation of the efficacy and safety of new drugs using validated and highly predictive models – with a strong cardiovascular focus.
At IPST we believe each study is worthy of tailored protocols designed to maximize the scientific and strategic value of the data generated. We believe in taking ownership of the studies entrusted to IPST while ensuring mutual collaboration for developing and agreeing to overall project plans.
Established in 1999, we have conducted more than 650 preclinical cardiac safety and efficacy studies and over 100 GLP-compliant studies in support of FDA, EMEA, Health Canada and MoHW. In 2014, IPST completed a major expansion of our laboratory and research office facility – increasing our capacity to get the right data the first time. Every time.
At IPST, our senior management team is fully engaged on every project. We invite our clients to talk through challenges, business requirements and quantitative expectations for each project. Our team understands the linkages between tasks, projects costs and schedules
We have a well-earned reputation for the sustained delivery of accurate results at a reasonable cost. IPST is proud of our applied science approach to addressing the needs of both start-up and mature biopharmaceutical and nutraceutical companies.